ZYMAR Drug Patent Profile
✉ Email this page to a colleague
When do Zymar patents expire, and what generic alternatives are available?
Zymar is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in ZYMAR is gatifloxacin. There are sixteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zymar
A generic version of ZYMAR was approved as gatifloxacin by LUPIN LTD on August 28th, 2013.
Summary for ZYMAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 140 |
| Patent Applications: | 5,223 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZYMAR |
| DailyMed Link: | ZYMAR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ZYMAR
Paragraph IV (Patent) Challenges for ZYMAR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ZYMAR | Ophthalmic Solution | gatifloxacin | 0.3 % | 021493 | 1 | 2007-07-19 |
US Patents and Regulatory Information for ZYMAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZYMAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Allergan | ZYMAR | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 021493-001 | Mar 28, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZYMAR
See the table below for patents covering ZYMAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1275081 | ⤷ Try a Trial | |
| Canada | 2307632 | PREPARATIONS LIQUIDES AQUEUSES PHARMACEUTIQUES (AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION) | ⤷ Try a Trial |
| China | 87100580 | ⤷ Try a Trial | |
| Australia | 694946 | ⤷ Try a Trial | |
| Japan | 2598737 | ⤷ Try a Trial | |
| Hungary | 203339 | PROCESS FOR PRODUCING NEW 8-ALKOXY-QUINOLONE-CARBOXYLIC ACID DERIVATIVES | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZYMAR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0230295 | 300110 | Netherlands | ⤷ Try a Trial | |
| 0230295 | C300110 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
